GlassScriptPhysician profile
Salvador Caputto
NPI 1972568731
$11,211.89
in general payments reported to CMS, 2019-2025
68 companies · $2,730 in 2025
The $2,730 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $237 · 2021: $918 · 2022: $1,587 · 2023: $2,244 · 2024: $2,429 · 2025: $2,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Long Term Medical Supply Or Device Loan: $798 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,487.99 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $117.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,000.93 | 2019-2025 | |
| Janssen Biotech, INC. | $889.30 | 2019-2025 | Darzalex, Imbruvica, Erleada |
| Merck Sharp & Dohme LLC | $634.97 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $443.06 | 2019-2025 | Itovebi, Venclexta, Tecentriq |
| Celgene Corporation | $438.88 | 2019-2025 | Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $438.40 | 2020-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $424.89 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Pfizer INC. | $390.64 | 2019-2025 | |
| Genzyme Corporation | $350.54 | 2019-2025 | |
| Astellas Pharma US INC | $302.11 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Astrazeneca Pharmaceuticals LP | $283.30 | 2020-2025 | Enhertu, Lynparza |
| Eisai INC. | $281.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.06 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $227.37 | 2019-2023 | |
| Beigene USA, INC. | $220.94 | 2020-2025 | Brukinsa |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvador Caputto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.